Novavax, Inc.
NVAXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Novavax, Inc. focuses on Biotechnology services and products. Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and. With a market capitalization of $1.35B, it sits in small-cap territory. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Market Cap
$1.35B
Beta
2.43
P/E (TTM)
—
P/E (Fwd)
-15.13
EPS (TTM)
$-0.56
EPS (Fwd)
$-0.54
ROE
—
ROA
2.0%
Cash
$790.3M
Total Debt
$295.1M
Free CF
$58.6M
52W Change
17.3%
Annual Financials
Cash vs Debt
Novavax, Inc. holds $790.3M in cash against $295.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $58.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROA of 2.0% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $1.60B to $1.12B.
With a beta above 1.5, NVAX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NVAX.